Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Stephanie Fradette

Stephanie Fradette

Head of Rare Neurology Development, Biogen

Appears in 1 story

Notable Quotes

"This designation reflects the FDA's determination that salanersen has the potential to demonstrate substantial improvement over available therapies." — Stephanie Fradette

Stories

Biogen's salanersen wins FDA breakthrough status for spinal muscular atrophy

New Capabilities

Leading salanersen's clinical program

Some children with spinal muscular atrophy get a one-time gene therapy, then slowly weaken again. There has been no clear next step for them. On June 4, 2026, the FDA gave Biogen's salanersen a designation meant to speed up that next step.

Updated Yesterday